daratumumab
janssen
['congrat', 'daratumumab', 'light chain']
emn prospective trial of stage iiib al amyloidosis with single agent daratumumab improves median os to 10 months, better than historical controls. #ash22 congratulations to dr kastritis. 
Director, Amyloidosis Center @BU_Amyloidosis Hematologist and Oncologist @The_BMC